Amidate(tm) Etomidate

Dosage of Etomidate must be individualized based on the patient's weight, clinical condition, and the specific requirements of the procedure. It is administered strictly by the intravenous route.

• Induction of Anesthesia: The standard dose for the induction of anesthesia in adult patients ranges from 0.2 mg/kg to 0.6 mg/kg of body weight. For a typical 70 kg adult, this equates to 14 mg to 42 mg. The injection should be administered over a period of 30 to 60 seconds to minimize the risk of side effects like myoclonus (involuntary muscle twitching).
• Procedural Sedation: For shorter procedures, lower doses (e.g., 0.1 mg/kg to 0.15 mg/kg) may be utilized, often in combination with an analgesic.

Etomidate is approved for use in pediatric patients, but its use is generally reserved for those older than 10 years of age.

• Children (10 years and older): The dosage is similar to that of adults, typically 0.2 mg/kg to 0.3 mg/kg.
• Children (under 10 years): Safety and efficacy have not been established by the FDA for patients under 10. However, in emergency medicine, it is sometimes used off-label by specialists at similar weight-based doses, though caution is required due to the potential for more pronounced adrenal suppression in younger children.

Renal Impairment

Specific dosage adjustments for renal (kidney) impairment are not formally defined in the manufacturer's labeling, as the primary metabolite is inactive. However, because the drug is highly protein-bound and uremia (buildup of toxins in the blood) can alter protein binding, clinicians often use the lower end of the dosing range and monitor the patient closely.

Hepatic Impairment

In patients with cirrhosis or severe hepatic (liver) impairment, the volume of distribution can be increased, and the clearance of Etomidate may be reduced. This can lead to a prolonged duration of action. A dose reduction or slower administration rate is often necessary.

Elderly Patients

Geriatric patients (aged 65 and older) are generally more sensitive to the hypnotic effects of Etomidate. They often have a smaller initial volume of distribution and slower clearance. Healthcare providers typically reduce the starting dose (e.g., 0.15 mg/kg to 0.2 mg/kg) and titrate carefully to avoid excessive sedation or respiratory depression.

Etomidate is not a medication that a patient takes at home. It is administered in a hospital or clinical setting by an anesthesiologist, CRNA, or emergency physician.

• Preparation: The medication is drawn into a syringe and should be inspected for particulate matter or discoloration. It should not be mixed with other medications in the same syringe.
• Administration: It is injected through a secure intravenous line. To reduce pain at the injection site, a larger vein (like the antecubital vein) is preferred, and sometimes a small dose of lidocaine is administered beforehand.
• Monitoring: Continuous monitoring of heart rate, blood pressure, oxygen saturation, and end-tidal CO2 is mandatory during and after administration.

Because Etomidate is administered as a single dose or short series of doses by a healthcare professional for a specific procedure, the concept of a 'missed dose' by a patient does not apply. If a procedure is delayed, the medical team will determine the appropriate timing for administration.

An overdose of Etomidate primarily manifests as an extension of its pharmacological action.

• Signs: Severe respiratory depression (slow or stopped breathing), hypotension (low blood pressure), and prolonged unconsciousness.
• Emergency Measures: There is no specific reversal agent (antidote) for Etomidate. Treatment is supportive. This includes maintaining a patent airway, providing supplemental oxygen or mechanical ventilation, and administering intravenous fluids or vasopressors if blood pressure drops significantly. Because of the drug's rapid redistribution and metabolism, the effects of an overdose usually resolve quickly if the patient is properly supported.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Only qualified medical personnel should handle this medication.

Etomidate is associated with several common side effects that occur during or immediately after administration. While usually transient, they require management by the clinical team.

• Myoclonus (Involuntary Muscle Twitching): This is perhaps the most common side effect, occurring in up to 70% of patients who do not receive premedication. It manifests as brief, shock-like jerks of the limbs or trunk. While it looks like a seizure, it is actually caused by the disinhibition of subcortical structures in the brain. It can be minimized by pre-administering a small dose of an opioid (like fentanyl) or a benzodiazepine (like midazolam).
• Pain on Injection: Because the standard formulation contains propylene glycol, many patients experience a sharp, stinging sensation at the IV site during the injection. This occurs in approximately 20-50% of patients.
• Nausea and Vomiting: Postoperative nausea and vomiting (PONV) is common with Etomidate, occurring more frequently than with propofol. It can be distressing for the patient during recovery.

• Apnea (Temporary Cessation of Breathing): While Etomidate is 'respiratory-sparing' compared to other drugs, brief periods of apnea (lasting 5-30 seconds) can occur immediately after a bolus dose, especially if given rapidly.
• Hyperventilation or Hypoventilation: Some patients may experience a temporary change in their breathing rate or depth.
• Hiccups: Transient hiccups are occasionally observed during the induction phase.
• Tachycardia or Bradycardia: While generally stable, some patients may experience a slight increase or decrease in heart rate.

• Laryngospasm: A rare but serious tightening of the vocal cords that makes breathing difficult.
• Cardiac Arrhythmias: Irregular heartbeats have been reported in rare instances, particularly in patients with underlying heart disease.
• Phlebitis: Inflammation of the vein used for injection, which may lead to redness and swelling.

> Warning: Stop taking Etomidate and call your doctor immediately if you experience any of these. (Note: These will typically be managed by your medical team in the hospital).

• Adrenal Suppression (Adrenocortical Insufficiency): Etomidate inhibits an enzyme called 11-beta-hydroxylase, which is necessary for the body to produce cortisol (the 'stress hormone'). Even a single dose can suppress cortisol production for 6 to 24 hours. In most healthy patients, this is not clinically significant. However, in patients with severe sepsis or septic shock, there is ongoing debate about whether this suppression increases the risk of mortality.
• Severe Anaphylaxis: Though extremely rare, life-threatening allergic reactions can occur. Symptoms include hives, swelling of the face or throat, and difficulty breathing.
• Severe Hypotension: While rare with Etomidate, a significant drop in blood pressure can occur in patients who are severely dehydrated or have certain types of heart block.

Etomidate is intended for short-term, acute use. It is not used for long-term sedation in the ICU (continuous infusion) because its effect on the adrenal glands is cumulative. Prolonged use can lead to significant adrenal failure, characterized by electrolyte imbalances, profound weakness, and an inability of the body to respond to stress. Clinical trials in the 1980s showed increased mortality when Etomidate was used for long-term sedation in trauma patients, leading to the abandonment of this practice.

No FDA black box warnings for Etomidate. Unlike some other anesthetics (like ketamine or propofol), Etomidate does not currently carry a boxed warning. However, the manufacturer's labeling includes strong precautions regarding its use in patients with known adrenal insufficiency and the high incidence of myoclonus.

Report any unusual symptoms to your healthcare provider. If you have a history of adrenal problems or porphyria, ensure your surgical team is aware before the procedure.

Etomidate should only be used by clinicians who are experienced in the administration of intravenous anesthetics and the management of their potential complications. Because it can cause rapid unconsciousness and potential respiratory depression, equipment for artificial airway maintenance, oxygen enrichment, and circulatory resuscitation must be immediately available.

One of the most critical safety points regarding Etomidate is its impact on the endocrine system. Patients and providers must be aware that Etomidate is a potent inhibitor of adrenal steroidogenesis. This means the body's natural ability to produce cortisol is temporarily 'turned off.' In high-stress situations like major surgery or severe infection, this can theoretically impair the body's stress response.

As of the current 2024-2026 clinical guidelines, there are no FDA black box warnings for Etomidate. It is considered a safe and effective induction agent when used as directed in appropriate clinical settings.

• Adrenal Insufficiency: Use with extreme caution in patients with known primary or secondary adrenal insufficiency. Because Etomidate inhibits the 11-beta-hydroxylation of steroid precursors, it can exacerbate existing hormone deficiencies. Some clinicians may choose to administer 'stress-dose' steroids (like hydrocortisone) if Etomidate must be used in these patients.
• Myoclonus and Seizure Disorders: While the muscle twitching (myoclonus) associated with Etomidate is not an epileptic seizure, it can be vigorous. Use caution in patients with fragile bones or injuries where sudden movement could be harmful. Interestingly, while it is not an anticonvulsant, it is sometimes used in Electroconvulsive Therapy (ECT) because it allows for longer, more effective seizures compared to other anesthetics.
• Porphyria: Etomidate has been associated with the induction of delta-aminolevulinic acid (ALA) synthetase, which can trigger an acute attack in patients with hereditary porphyria (a group of rare blood disorders). It should generally be avoided in these individuals.
• Pain and Venous Irritation: To minimize the risk of local tissue damage or phlebitis, the drug should be injected into larger veins, and the integrity of the IV line should be confirmed prior to administration.

Patients receiving Etomidate require intensive monitoring:

1. 1Hemodynamics: Continuous ECG and frequent blood pressure checks (every 1-2 minutes during induction).
2. 2Respiratory Status: Pulse oximetry (oxygen levels) and capnography (CO2 levels) are standard.
3. 3Adrenal Function: While routine testing of cortisol levels is not required for a single dose in healthy patients, it may be considered in critically ill patients who show signs of unexpected hemodynamic instability after the drug has worn off.

Etomidate causes significant impairment of cognitive and motor functions. Patients must not drive, operate heavy machinery, or make important legal decisions for at least 24 hours after receiving Etomidate. A responsible adult must accompany the patient home after discharge from a surgical center.

Alcohol is a potent central nervous system (CNS) depressant. Consuming alcohol within 24 hours before or after receiving Etomidate can lead to dangerous levels of sedation and respiratory depression. Patients should be advised to abstain from alcohol during the perioperative period.

Etomidate is used as a single-dose induction agent; therefore, 'tapering' is not applicable. There is no withdrawal syndrome associated with a single clinical dose. However, its effects on the adrenal glands can persist for several hours after the sedative effects have vanished.

> Important: Discuss all your medical conditions with your healthcare provider before starting Etomidate, especially any history of adrenal disease or porphyria.

While there are few drugs that are strictly contraindicated for co-administration in a 'never use' sense, certain combinations are avoided due to the risk of severe CNS depression or metabolic interference.

• Ketoconazole: This antifungal medication is also a potent inhibitor of adrenal steroidogenesis. Using Etomidate and ketoconazole together can lead to profound and prolonged adrenal suppression. If a patient is on chronic ketoconazole, an alternative induction agent is often preferred.
• Other Carboxylated Imidazoles: Co-administration with similar chemical structures is generally avoided to prevent cumulative toxicity.

• CNS Depressants (Opioids, Benzodiazepines, Barbiturates): These drugs synergize with Etomidate. While they are often used together intentionally (e.g., Fentanyl given before Etomidate), the combination significantly increases the risk of apnea and hypotension. The dose of each agent should be reduced accordingly.
• Inhalational Anesthetics (Sevoflurane, Isoflurane): These gases also depress the CNS and cardiovascular system. When Etomidate is used for induction, the 'wash-in' of the gas must be managed carefully to avoid an excessive depth of anesthesia.
• Neuromuscular Blocking Agents (Succinylcholine, Rocuronium): Etomidate does not interfere with the action of muscle relaxants, but the timing is critical. Because Etomidate has a very fast onset, the muscle relaxant must be administered promptly to facilitate intubation before the Etomidate wears off.

• Antihypertensive Medications: Patients on chronic beta-blockers, ACE inhibitors, or calcium channel blockers may have a blunted compensatory response to the minor hemodynamic changes caused by Etomidate. While Etomidate is the safest choice for these patients, blood pressure should still be monitored closely.
• Verapamil: Some studies suggest verapamil may slightly prolong the hypnotic effect of Etomidate by interfering with its metabolism.

• General Fasting: Because Etomidate is used for general anesthesia, patients must follow standard 'NPO' (nothing by mouth) guidelines (usually no food for 6-8 hours and no clear liquids for 2 hours before the procedure) to prevent aspiration (vomiting food into the lungs).
• Grapefruit Juice: While grapefruit juice inhibits CYP3A4, the impact on a single IV dose of Etomidate is clinically negligible, though it is best avoided in the 24 hours prior to surgery.

• Valerian Root, St. John's Wort, and Kava: These supplements have sedative properties and can interact with GABA receptors. They may prolong the recovery time from Etomidate anesthesia. Patients are generally advised to stop herbal supplements 1-2 weeks before elective surgery.

• Cortisol Stimulation Tests (ACTH Stimulation): Etomidate will cause a 'false' result on an ACTH stimulation test. Because it blocks the production of cortisol, the adrenal glands will not respond to the ACTH injection. This effect can last for up to 24 hours after a single dose.
• Thyroid Function Tests: There is some evidence that Etomidate may transiently affect thyroid hormone binding, though this is rarely clinically significant.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those taken for chronic conditions like high blood pressure or anxiety.

Conditions where Etomidate must NEVER be used include:

• Known Hypersensitivity: If a patient has a documented severe allergic reaction (anaphylaxis) to Etomidate or any of the components in the formulation (such as propylene glycol or the lipid emulsion), the drug is strictly contraindicated. The mechanism is an IgE-mediated immune response that can lead to airway collapse and shock.
• Acute Porphyria: Etomidate is considered 'porphyrinogenic.' In patients with conditions like Acute Intermittent Porphyria (AIP), the drug can induce the enzyme ALA synthase, leading to the accumulation of toxic porphyrins. This can cause severe abdominal pain, neurological damage, and psychiatric symptoms.

Conditions requiring careful risk-benefit analysis include:

• Sepsis and Septic Shock: This is the most debated area of Etomidate use. Patients in septic shock already have 'relative adrenal insufficiency.' Adding Etomidate can further suppress their cortisol levels. Some large-scale studies (like the CORTICUS trial) have suggested a link between Etomidate and increased mortality in sepsis, while others have not. Many clinicians now prefer ketamine for septic patients.
• Severe Hepatic Cirrhosis: Due to the reduced metabolism and altered volume of distribution, the risk of prolonged sedation is high.
• Labor and Delivery: Etomidate crosses the placenta. While it can be used for emergency Cesarean sections, it may cause transient adrenal suppression in the newborn.
• Pre-existing Adrenal Insufficiency: In patients with Addison's disease, Etomidate should be used only if no other safe alternative exists, and only with concurrent steroid replacement.

There is no known major cross-sensitivity between Etomidate and other common anesthetics like propofol or barbiturates. However, patients allergic to eggs or soy should check the specific formulation, as some lipid-based Etomidate emulsions may contain these ingredients.

> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic conditions or previous reactions to anesthesia, before prescribing Etomidate.

Etomidate is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.

• Risks: Etomidate crosses the placental barrier. If used during labor or for a C-section, the concentration in the fetal blood can reach about 50% of the maternal concentration. This can lead to temporary adrenal suppression in the neonate.
• Clinical Use: It is generally reserved for pregnant patients where hemodynamic stability is paramount (e.g., a mother with severe heart disease requiring emergency surgery) and the benefits outweigh the potential risks to the fetus.

It is not known whether Etomidate is excreted in human milk. However, because the drug is rapidly cleared from the mother's system (half-life of 3-5 hours), the amount a nursing infant would receive is likely very small.

• Recommendation: Most guidelines suggest that breastfeeding can be resumed once the mother is fully awake and alert following the procedure, typically 4 to 6 hours after administration.

• Approved Age: FDA-approved for children 10 years of age and older.
• Considerations: In children, the volume of distribution is larger and the clearance is faster than in adults, meaning they may require slightly higher weight-based doses (0.3 mg/kg).
• Risks: The risk of myoclonus is particularly high in children. Premedication with an opioid is strongly recommended to prevent distressing movements during induction.

• Pharmacokinetics: Elderly patients have a lower 'initial volume of distribution,' meaning the drug stays in the blood at higher concentrations for longer. They also have reduced hepatic blood flow.
• Risks: There is an increased risk of hypotension and prolonged emergence (waking up) from anesthesia.
• Dosing: A reduced dose (e.g., 0.1 mg/kg to 0.2 mg/kg) is usually sufficient for induction in patients over 65.

In patients with kidney failure, the pharmacokinetics of Etomidate are not significantly altered because the liver handles the primary metabolism. However, the inactive metabolites can accumulate. No specific dose adjustment is required, but clinical monitoring for delayed recovery is prudent.

• Impact: The liver is the primary site of Etomidate metabolism. In patients with cirrhosis or hepatitis, the half-life can be doubled.
• Adjustment: Doses should be titrated slowly, and clinicians should be prepared for a significantly longer duration of sedation.

> Important: Special populations require individualized medical assessment by an anesthesiology professional to ensure the safest possible outcome.

Etomidate is a GABA-A receptor agonist. Specifically, it binds to the beta-subunits of the GABA-A receptor complex in the central nervous system. This binding increases the affinity of the receptor for the inhibitory neurotransmitter GABA. When GABA binds, the chloride channel opens, chloride ions flow into the post-synaptic neuron, and the cell becomes hyperpolarized. This inhibits neuronal firing, leading to the rapid induction of a hypnotic state. Etomidate is unique because it is highly selective for these receptors and has almost no effect on other neurotransmitter systems (like NMDA or acetylcholine), which explains its lack of analgesic or muscle-relaxant properties.

• CNS Effects: Etomidate reduces the Cerebral Metabolic Rate of Oxygen (CMRO2) and reduces Cerebral Blood Flow (CBF), which leads to a decrease in Intracranial Pressure (ICP). This makes it useful for patients with head injuries.
• Cardiovascular Effects: Etomidate is noted for its 'hemodynamic neutrality.' It does not cause the release of histamine and has minimal effects on myocardial contractility (the heart's pumping strength).
• Endocrine Effects: It causes a dose-dependent inhibition of 11-beta-hydroxylase, the enzyme that converts 11-deoxycortisol to cortisol. This inhibition is extremely potent and occurs at doses lower than those required for hypnosis.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV only) |

| Protein Binding | 76% (primarily to Albumin) |

| Half-life (Elimination) | 2.9 - 5.3 hours |

| Tmax (Onset) | 30 - 60 seconds |

| Metabolism | Hepatic (Hydrolysis by esterases) |

| Excretion | Renal 75%, Fecal 13% |

• Molecular Formula: C14H16N2O2
• Molecular Weight: 244.29 g/mol
• Solubility: Poorly soluble in water at neutral pH; formulated in propylene glycol or lipid emulsion.
• Structure: It is the R-(+) isomer of ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate. The R-(+) isomer is 10 times more potent as a hypnotic than the S-(-) isomer.

Etomidate is classified as a General Anesthetic, Systemic; Hypnotic, Non-Barbiturate. It is part of the EPC (Established Pharmacologic Class) of General Anesthetics. Related medications include Propofol, Methohexital, and Thiopental, though Etomidate is chemically distinct as an imidazole derivative.